List of medicinal products under additional monitoring
Submitted by Anonymous (not verified) on 29 July 2024 - 12:58
List of medicinal products under additional monitoring
CTIS newsflash - 26 July 2024
Submitted by Anonymous (not verified) on 29 July 2024 - 8:47
CTIS newsflash - 26 July 2024
Concept paper for the development of a guideline on the demonstration of therapeutic equivalence for nasal products
Submitted by Anonymous (not verified) on 26 July 2024 - 15:00
Concept paper for the development of a guideline on the demonstration of therapeutic equivalence for nasal products
Dossier requirements for anticancer medicinal products for dogs and cats - Scientific guideline
Submitted by Anonymous (not verified) on 26 July 2024 - 14:13
Dossier requirements for anticancer medicinal products for dogs and cats - Scientific guideline
Concept paper on the revision of the guideline on dossier requirements for anticancer medicinal products for dogs and cats
Submitted by Anonymous (not verified) on 26 July 2024 - 14:10
Concept paper on the revision of the guideline on dossier requirements for anticancer medicinal products for dogs and cats
New fee regulation: webinar for veterinary marketing authorisation holders, Online, European Medicines Agency, Amsterdam, the Netherlands, from 20 June 2024, 10:00 (CEST) to 20 June 2024, 11:00 (CEST)
Submitted by Anonymous (not verified) on 26 July 2024 - 14:06
New fee regulation: webinar for veterinary marketing authorisation holders, Online, European Medicines Agency, Amsterdam, the Netherlands, from 20 June 2024, 10:00 (CEST) to 20 June 2024, 11:00 (CEST)
Records of data processing activity for digital business cards (QR code)
Submitted by Anonymous (not verified) on 26 July 2024 - 13:45
Records of data processing activity for digital business cards (QR code)
Orphan designation: Acetylleucine Treatment of ataxia-oculomotor apraxia, 16/04/2024 Positive
Submitted by Anonymous (not verified) on 26 July 2024 - 13:40
Orphan designation: Acetylleucine Treatment of ataxia-oculomotor apraxia, 16/04/2024 Positive
Orphan designation: annamycin Treatment of acute myeloid leukaemia, 16/04/2024 Positive
Submitted by Anonymous (not verified) on 26 July 2024 - 13:40
Orphan designation: annamycin Treatment of acute myeloid leukaemia, 16/04/2024 Positive
Orphan designation: Humanised IgG1 (K322A) monoclonal antibody against disialoganglioside GD2 Treatment of neuroblastoma, 16/04/2024 Positive
Submitted by Anonymous (not verified) on 26 July 2024 - 13:40
Orphan designation: Humanised IgG1 (K322A) monoclonal antibody against disialoganglioside GD2 Treatment of neuroblastoma, 16/04/2024 Positive